LEO drops OTC focus
This article is powered by OTC Bulletin & The Rose Sheet
Executive Summary
LEO Pharma will “no longer pursue OTC in most markets” as it intensifies its focus on “new innovative solutions for medical dermatology”, the Danish firm has revealed.